Showing 1941-1950 of 4063 results for "".
- AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsiahttps://modernod.com/news/agtc-announces-completion-of-enrollment-in-all-adult-dose-groups-of-its-ongoing-phase-1-2-clinical-trials-in-patients-with-achromatopsia/2477389/Applied Genetic Technologies Corporation (AGTC) announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its phase 1/2 clinical programs with achromatopsia due to mutation in the
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- AGTC Reports Positive 6-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-reports-positive-6-month-data-from-its-ongoing-phase-1-2-clinical-trial-in-x-linked-retinitis-pigmentosa/2477218/Gene therapy company Applied Genetic Technologies Corporation (AGTC) reported positive interim 6-month data from its ongoing phase 1/2 clinical program in X-linked retinitis pigmentosa (XLRP). The results show that patients treated
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DMEhttps://modernod.com/news/oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of-dme/2476439/Oxurion NV announced that all patients have been enrolled in its phase 2 trial evaluating its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabeti
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- Trump Health Official Says COVID Patients Should Not Re-Test. ‘It’s clogging up the system.’https://modernod.com/news/trump-health-official-says-covid-patients-should-not-re-test-its-clogging-up-the-system/2478038/The Trump administration plans to release guidance that non-hospitalized patients who test positive for COVID-19 do not need a second test to confirm they are clear of the virus, according to a FierceHealthcare
- Chinese Official Claims Fujifilm’s Avigan “Clearly Effective” in Treating COVID-19https://modernod.com/news/chinese-official-claims-fujifilms-avigan-clearly-effective-in-treating-covid-19/2477411/Results of clinical studies conducted in China suggest that Fujifilm’s Avigan (favipiravir) may be effective at treating patients with COVID-19. Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, remarked “it